metadata
library_name: setfit
tags:
- setfit
- sentence-transformers
- text-classification
- generated_from_setfit_trainer
metrics:
- accuracy
widget:
- text: "johnson johnsons cell therapy carvykti shows better survival rate in pretreated blood cancer patients finanzenat\n\n blob \n\natx atx \_ \_ dax dax \_ \_ dow dow \_ \_ estoxx estoxx \_ \_ nasdaq nasdaq \_ \_ öl öl \_ euro euro \_ chf chf \_ gold gold \_ \_\n\natx atx \_ \_ dax dax \_ \_ dow dow \_ \_ estoxx estoxx \_ \_ nasdaq nasdaq \_ \_ öl öl \_ euro euro \_ chf chf \_ gold gold \_ \_\n\n\_javascriptvoid\n\n\_ \_\n\ndepot eröffnen\n\n\_javascriptvoid\n\n menujavascriptvoid\n\n börse\n\n aktien\n \n\n aktienkurse\n aktiensuche\n realtimekurse\n \n\n atxliste\n atx primeliste\n eurostoxxliste\n daxliste\n dow jonesliste\n nikkeiliste\n spliste\n rohstoffe\n devisen\n\n listen\n \n\n topflop\n indizes\n branchen\n\n termine\n \n\n hauptversammlung\n quartalszahlen\n wirtschaftsdaten\n dividendenausschüt\n\n dividenden\n börsesocial\n\n indizes\n \n\n listen\n \n\n topflop\n indizes\n\n realtimekurse\n \n\n indizes\n listen\n\n emerging markets\n\n zertifikate\n \n\n suche\n basiswerte\n \n\n indizes\n aktien\n baskets\n währungen\n rohstoffe\n zinsen anleihen\n sonstige\n\n produkttypen\n \n\n airbag\n aktienanleihen\n alpha\n basket\n bonus\n discount\n exotische os\n express\n faktor tracker\n indextracker\n inlineos\n garantie\n knockout\n optionsscheine\n outperformance\n sonst zertifikate\n sprint\n\n tools\n \n\n zertifikatematrix\n emittentenmatrix\n knockout map\n\n news\n neuemissionen\n\n hebelprodukte\n \n\n ossuche\n kosuche\n basiswerte\n \n\n indizes\n aktien\n baskets\n währungen\n rohstoffe\n zinsen anleihen\n sonstige\n\n produkttypen\n \n\n airbag\n aktienanleihen\n alpha\n basket\n bonus\n discount\n exotische os\n express\n faktor tracker\n indextracker\n inlineos\n garantie\n knockout\n optionsscheine\n outperformance\n sonst zertifikate\n sprint\n\n tools\n \n\n zertifikatematrix\n emittentenmatrix\n knockout map\n\n news\n neuemissionen\n\n fonds\n \n\n suche\n news\n kvgs\n\n etf\n \n\n suche\n news\n kvgs\n\n anleihen\n \n\n suche\n news\n\n rohstoffe\n \n\n news\n realtimekurse\n goldmünzen\n\n devisen\n \n\n news\n währungsrechner\n realtimekurse\n kryptowährungen\n kryptobroker vergleich\n\n zinsen\n \n\n news\n libor\n euribor\n leitzins\n\n cfds\n \n\n news\n\n trading\n \n\n hebelprodukte\n optionsscheine\n realtimekurse\n \n\n atxliste\n atx primeliste\n eurostoxxliste\n daxliste\n rohstoffe\n devisen\n\n bitcoin kaufen\n\n kryptos\n brokervergleiche\n \n\n brokervergleich\n kryptobrokervergleich\n cfdbrokervergleich\n\n forum\n\n news analysen\n\n news\n \n\n ressorts\n \n\n aktien\n anleihen\n cfds\n devisen\n etf\n fonds\n rohstoffe\n zertifikate\n private finanzen\n zinsen\n\n rubriken\n \n\n chartanalysen\n emittentennews\n fondsgesellschaft news\n heute im fokus\n interviews\n konjunktur\n zinsen\n\n quellen\n \n\n apa\n aktiencheck\n businesswire\n dow jones newswires\n dpaafx\n\n heute im fokus\n nachrichtenarchiv\n\n analysen\n experten kolumnen\n atx news\n\n myfinanzen\n\n anmelden\n registrieren\n passwort vergessen\n mein profil\n portfolio\n watchlist\n\n zero depot\n etfsparplan\n krypto kaufen\n ratgeber\n\n suchenjavascriptvoid\n \n \n\nanmelden registrieren fan werden\n\n\_ \_\n\n börse börse\n news analysen news analysen\n myfinanzen myfinanzen\n zero depot zero depot\n etfsparplan etfsparplan\n krypto kaufen krypto kaufen\n ratgeber ratgeber\n\n news news\n analysen analysen\n experten kolumnen experten kolumnen\n atx news atx news\n\n ressorts ressorts\n \n aktien aktien\n anleihen anleihen\n cfds cfds\n devisen devisen\n etf etf\n fonds fonds\n rohstoffe rohstoffe\n zertifikate zertifikate\n private finanzen private finanzen\n zinsen zinsen\n rubriken rubriken\n \n chartanalysen chartanalysen\n emittentennews emittentennews\n fondsgesellschaft news fondsgesellschaft news\n heute im fokus heute im fokus\n interviews interviews\n konjunktur konjunktur\n zinsen zinsen\n quellen quellen\n \n apa apa\n aktiencheck aktiencheck\n businesswire businesswire\n dow jones newswires dow jones newswires\n dpaafx dpaafx\n heute im fokus heute im fokus\n nachrichtenarchiv nachrichtenarchiv\n\nhome home »\n\naktien aktien »\n\nin holdingsaktie in holdingsaktie »\n\nnachrichten zu in holdings nachrichten zu in holdings »\n\njohnson johnsons cell therapy carvykti shows better survival rate in pretreated blood cancer patients\n\nin holdings aktie isin jp in holdings co ltd registered shs aktie\n\n\nin holdings aktie isin jp in holdings co ltd registered shs aktie\n\n\njavascriptvoid druckansicht\n\nkurse charts realtime\n\nnews analysen\n\nfundamental\n\nunternehmen\n\nzugeh wertpapiere\n\naktion\n\nkurs chart in holdings co ltd registered shs kurs\n\nchart groß in holdings co ltd registered shs chartanalyse\n\nnews adhoc in holdings co ltd registered shs news adhoc\n\nbilanzguv in holdings co ltd registered shs bilanzguv\n\ntermine in holdings co ltd registered shs termine\n\nzertifikate in holdings co ltd registered shs zertifikate\n\nportfoliojavascriptvoid\n\ntimes sales in holdings co ltd registered shs times and sales\n\nchartvergleichjavascriptoeffneneuesfenster in holdings co ltd registered shs chartvergleich\n\nanalysen in holdings co ltd registered shs analysen\n\nschätzungen in holdings co ltd registered shs schätzungen\n\nprofil in holdings co ltd registered shs profil\n\noptionsscheine in holdings co ltd registered shs optionsscheine\n\nwatchlistjavascriptvoid\n\nbörsenplätze in holdings co ltd registered shs börsenplätze\n\nrealtime push in holdings co ltd registered shs realtime push\n\nkursziele in holdings co ltd registered shs kursziele\n\ndividendegv in holdings co ltd registered shs dividendegv\n\nknockouts in holdings co ltd registered shs knockouts\n\nhistorisch historisch in holdings\n\nanalysen in holdings co ltd registered shs fundamentalanalyse\n\n\n\nkurse charts realtime\n\nkurs chart in holdings co ltd registered shs kurs\n\ntimes sales in holdings co ltd registered shs times and sales\n\nbörsenplätze in holdings co ltd registered shs börsenplätze\n\nhistorisch historisch in holdings\n\n\n\n\n\nnews analysen\n\nnews adhoc in holdings co ltd registered shs news adhoc\n\nanalysen in holdings co ltd registered shs analysen\n\nkursziele in holdings co ltd registered shs kursziele\n\n\n\n\n\nfundamental\n\nbilanzguv in holdings co ltd registered shs bilanzguv\n\nschätzungen in holdings co ltd registered shs schätzungen\n\ndividendegv in holdings co ltd registered shs dividendegv\n\nanalysen in holdings co ltd registered shs fundamentalanalyse\n\n\n\n\n\nunternehmen\n\ntermine in holdings co ltd registered shs termine\n\nprofil in holdings co ltd registered shs profil\n\n\n\n\n\nzugeh wertpapiere\n\nzertifikate in holdings co ltd registered shs zertifikate\n\noptionsscheine in holdings co ltd registered shs optionsscheine\n\nknockouts in holdings co ltd registered shs knockouts\n\n\n\n \n\njohnson johnsons cell therapy carvykti shows better survival rate in pretreated blood cancer patients\n\n\na\n\na\n\nteilen\n\ndrucken\n\nthis article johnson johnsons cell therapy carvykti shows better survival rate in pretreated blood cancer patients originally appeared on benzingacomweiter zum vollständigen artikel bei benzinga zum vollständigen artikel weiter zum vollständigen artikel bei benzinga\n\n\n\nder finanzenat ratgeber für aktien \nwenn sie mehr über das thema aktien erfahren wollen finden sie in unserem ratgeber viele interessante artikel dazu \njetzt informieren\n\n \n\n \n\ndas könnte sie auch interessieren\n\nempfohlen von \n\nnachrichten zu in holdings co ltd registered shsmehr nachrichten nachrichten zu in holdings co ltd registered shs\n\n\n relevant\n alle\n vom unternehmen\n \n\n \n\n\n\nsuperreichensteuer so viel könnte sie in deutschland einbringen superreichensteuer so viel könnte sie in deutschland einbringen spiegel online spiegel online\n\n\n\ninflation energie und nahrungsmittel dämpfen inflation in deutschland inflation energie und nahrungsmittel dämpfen inflation in deutschland handelsblatt handelsblatt\n\n\n\nchemie basf schließt zwei weitere anlagen in deutschland chemie basf schließt zwei weitere anlagen in deutschland handelsblatt handelsblatt\n\n\n\nautobauer bmw ruft in den usa fast autos zurück autobauer bmw ruft in den usa fast autos zurück handelsblatt handelsblatt\n\n\n\nuk economy grows by in may uk economy grows by in may financial times financial times\n\n\n\nciti fined mn for compliance failures in further blow to overhaul citi fined mn for compliance failures in further blow to overhaul financial times financial times\n\n\n\nciti fined mn for compliance failures in further blow to overhaul citi fined mn for compliance failures in further blow to overhaul financial times financial times\n\n\n\nuk announces biggest overhaul of listings regime in decades uk announces biggest overhaul of listings regime in decades financial times financial times\n\nanalysen zu in holdings co ltd registered shsmehr analysen analysen zu in holdings co ltd registered shs\n\n\n alle\n buy\n hold\n sell\n \n\n \n\n \n\n \n\n \n\n \n\n \n\neintrag hinzufügen eintrag bearbeiten\n\nhinweis sie möchten dieses wertpapier günstig handeln sparen sie sich unnötige gebühren bei finanzennet brokerage handeln sie ihre wertpapiere für nur euro orderprovision pro trade hier informieren\n\nerfolgreich hinzugefügt zu portfoliowatchlist wechseln\n\nes ist ein fehler aufgetreten\n\nkein portfolio vorhanden bitte zusätzlich den namen des neuen portfolios angeben keine watchlisten vorhanden bitte zusätzlich den namen der neuen watchlist angeben\n\n \n\nportfolioname watchlistname\n\n \n\nportfolio\n\nname\n\ntyp\n\nisin\n\nbörse\n\nanzahl\n\naktueller kurs\n\nkurszeit\n\nkaufpreis\n\n \n\nkaufdatum\n\n \n\nkaufwert\n\n eur\n\nhinzufügen speichern\n\nnewssuche\n\n\ngojavascriptvoid\n\naktien in diesem artikel\n\n\n \n\nin holdings co ltd registered shs\n\n\n\n\n\nin holdings co ltd registered shsblob\n\nbörse aktuell live ticker\n\n\natx schließt in rot dax schließlich tiefer asiens börsen letztlich im minus der heimische aktienmarkt zeigte sich in rot der deutsche aktienmarkt präsentierte sich am mittwoch leichter die usbörsen weisen kursverluste aus die börsen in fernost verbuchten zur wochenmitte verluste\n\nnachrichten\n\n\n nachrichten zu aktien\n alle nachrichten\n\n\n\nkering stimmt auf weiteren gewinneinbruch ein gucci erneut schwach kering stimmt auf weiteren gewinneinbruch ein gucci erneut schwach\n\n\n\ncairn homes plc holdings in company cairn homes plc holdings in company\n\n\n\nausblick lpkf laser electronics zieht bilanz zum abgelaufenen quartal ausblick lpkf laser electronics zieht bilanz zum abgelaufenen quartal\n\n\n\nfuller smith turner plc transaction in own shares fuller smith turner plc transaction in own shares\n\n\n\nteslas q disappoints but theres more to the story teslas q disappoints but theres more to the story\n\n\n\ngericht pauschaler geldbetrag für bezahlkarte rechtswidrig gericht pauschaler geldbetrag für bezahlkarte rechtswidrig\n\n\n\nreise israelischer delegation nach katar verschiebt sich reise israelischer delegation nach katar verschiebt sich\n\n\n\nausblick totalenergies stellt quartalsergebnis zum abgelaufenen jahresviertel vor ausblick totalenergies stellt quartalsergebnis zum abgelaufenen jahresviertel vor\n\n\n\neaton declares quarterly dividend payable august eaton declares quarterly dividend payable august \n\n\n\naktie im fokus alphabet leiden unter sorgen um das kigeschäft aktie im fokus alphabet leiden unter sorgen um das kigeschäft\n\npagehit\n\naktien kaufen zu \ntopkonditionen\n\naktien etfs derivate kryptos und mehr – jetzt für \_euro pro trade handeln zzgl marktüblicher spreads\n\njetzt informieren\n\nfinanzennet apps\n\n finanzennet ios appblob android appblob\n\nfinanzennet appsblob\n\n \n\noskarblob etfsparplan\n\noskar ist der einfache und intelligente etfsparplan er übernimmt die etfauswahl ist steuersmart transparent und kostengünstig\n\njetzt mehr erfahren\n\n finanzenat bei facebook finanzenat rss feed\n\nwie bewerten sie diese seite\n\nschlecht sehr gut\n\n \n \naktien atx\_ dax\_ eurostoxx \_ dow jones\_ nasdaq \_ nikkei \_ sp \_ \n \nkontakt\_ \_impressum\_\_werbung\n\nsitemap\_ \_datenschutz\_ \_disclaimer\_ \_agb\_ \_privatsphäreeinstellungen\n\n \n\nfür die aufgeführten inhalte kann keine gewährleistung für die vollständigkeit richtigkeit und genauigkeit übernommen werden \nkursinformationen von six financial information deutschland gmbh verzögerung min nasdaq nyse min \n© finanzennet gmbh\n\nwerbehinweise die billigung des basisprospekts durch die bundesanstalt für finanzdienstleistungsaufsicht ist nicht als ihre befürwortung der angebotenen wertpapiere zu verstehen wir empfehlen interessenten und potenziellen anlegern den basisprospekt und die endgültigen bedingungen zu lesen bevor sie eine anlageentscheidung treffen um sich möglichst umfassend zu informieren insbesondere über die potenziellen risiken und chancen des wertpapiers sie sind im begriff ein produkt zu erwerben das nicht einfach ist und schwer zu verstehen sein kann\n\nhinweis zu plus der kleinanlegerkonten verlieren geld beim cfdhandel mit diesem anbieter sie sollten überlegen ob sie es sich leisten können das hohe risiko einzugehen ihr geld zu verlieren plusuk ltd ist zugelassen und reguliert durch financial conduct authority frn pluscy ltd authorized regulated by cysec \n\n \nwährungsrechner\_ news\_ devisen\_ dollarkurs\_ aktienkurse\_ bitcoin\_ rohstoffe\_ fonds"
- text: >-
expanding roles new approaches for pharmacists in managing graftvshost
disease
contemporary clinic contemporary clinic
otc guide otc guide
pharmacy times
ptce ptce
pharmacist moms group pharmacist moms group
blob logo
news
all news releases
media
all videos detail corner world news exchange consult pearls webcast voices
conferences
conference coverage listing
publications
pharmacy times practice in focus oncology practice in focus health systems
careers publications the publications submission a manuscript a peer
reviewer
clinical
b compounding pharmacy disease dermatitis disorder health cancer difficile
health cancer kidney disease lymphocytic leukemia cancer and cold health
eye disease care updates of pharmacy cancer health failure disease cancer
degeneration health myeloma sclerosis cancer management disease heroes
management cancer arthritis health syncytial virus arthritis cancer
pharmacy and supplements management health
events
upcoming events webinars
cmece
resources
clinical forum patient for the pharmacist tools
subscribe
blob logo
spotlight
communityretail technician
clinical role
communityretail technician pharmacy
clinical
coronavirus health health failure and supplements
supplement spotlight
october pharmacy technician edition
news
all news releases
media
all videos detail corner world news exchange consult pearls webcast voices
conferences
conference coverage listing
publications
pharmacy times practice in focus oncology practice in focus health systems
careers publications the publications submission a manuscript a peer
reviewer
clinical
b compounding pharmacy disease dermatitis disorder health cancer difficile
health cancer kidney disease lymphocytic leukemia cancer and cold health
eye disease care updates of pharmacy cancer health failure disease cancer
degeneration health myeloma sclerosis cancer management disease heroes
management cancer arthritis health syncytial virus arthritis cancer
pharmacy and supplements management health
events
upcoming events webinars
cmece
resources
clinical forum patient for the pharmacist tools
subscribe
advertisement
clinical role
communityretail
hospital
oncology
pharmacy technician
student
expanding roles new approaches for pharmacists in managing graftvshost
disease
june
by gillian mcgovern assistant editor
publication
article
pharmacy practice in focus oncologyjune
volume
issue
when treating patients with graftvshost disease pharmacists are often
responsible for selecting treatment regimens while navigating other
spheres of care
blob medical panelists credit africa studio stockadobecom
credit africa studio stockadobecom
there is no consensus when treating patients with graftvshost disease gvhd
because of the varying disease states and different interpretations among
providers explained amir ali pharmd bcop during a pharmacy times clinical
forum discussion ali is a clinical pharmacist specialist in
hematologyoncology and bone marrow transplant bmt at the university of
southern california norris comprehensive cancer center in los angeles as
the treatment landscape for gvhd continues to develop and new data emerge
pharmacists can develop more individualized regimens for patients while
finding their roles in treatment management are expanding
although steroids are typically the universal option for frontline
treatment ali emphasized that longterm steroid use isn’t ideal due to
adverse events aes—such as fibrosis which can be irreversible in patients
with chronic gvhd cgvhd—and the possibility of disease becoming refractory
according to ali there are only fdaapproved agents for the treatment of
patients with gvhd ibrutinib imbruvica janssen biotech inc pharmacyclics
llc which was approved in belumosudil rezurock kadmon pharmaceuticals llc
which was approved in july and ruxolitinib jakafi incyte which was
approved in september and has indications for cgvhd
as an example ali highlighted a patient who had cgvhd in the skin and
joints further he decided not to treat the patient with ibrutinib due to
the lack of efficacy shown in data from clinical trials using other data
he chose to treat the patient with belumosudil because it demonstrated
response rates in approximately of patients who received the treatment
realworld data ali said can be important for health care providers when
determining individualized treatment plans for patients
because steroids aren’t ideal in the long term there are different
practices in place to remove patients from this highdose treatment as soon
as possible whether it’s adhering to a particular timeline or tapering
according to tina gu pharmd bcop clinical pharmacist in pediatric
hematologyoncology and bmt at the university of california san francisco
ucsf benioff children’s hospital her practice tends to taper patients off
steroids before they develop refractory disease or experience aes
“our standard is to try to start tapering after weeks of highdose
steroids but what we’re seeing more at our hospital is adding a second
agent earlier on so we’re not even waiting for patients with gvhd to
develop steroidrefractory disease and we’re adding a second oral agent
earlier because our providers are anticipating that it’s already going to
be hard to taper patients off their steroids so by adding the
steroidsparing agent providers may be more successful in getting them off
these agents” gu said during the discussion
furthermore during the tapering of steroids patients may experience
cgvhdrelated exacerbation or recurrence pharmacists may want to increase
the dose or begin switching the patient to a new drug sandy on pharmd
clinical pharmacist in hematology and bmt at stanford health care in
california noted that although her institution wants patients off steroids
as soon as possible she continues the use of steroids because she is
already considering what additional treatment can be used currently and in
secondline treatment additionally for patients who experience a partial
response to steroids the next steps can be determined depending on which
organ system is involved in the patient’s gvhd state
angela lee pharmd bcop clinical pharmacist in hematologyoncology bmt and
cellular therapies at ucsf said that addon treatments can rely heavily on
patient characteristics such as their response to steroids which organs
are affected by their gvhd or the individual drug’s mechanism of action
“addon treatment also depends on the organ affected because there are some
data that show belumosudil may be more effective in the lung setting for
patients who present with lung disease up front that may be something that
is considered along with their regimen” lee said during the discussion
“for what ali was mentioning earlier it also depends on the mechanism of
action such as ruxolitinib if providers want to target cgvhd earlier they
might want to consider using that first”
pharmacists particularly bmt pharmacists have a significant role when
caring for patients with gvhd according to the panelists pharmacists are
typically the most constant health care professionals whom patients see
when receiving treatment for their disease state especially in gvhd
treatment pharmacists tend to know the data better than other health care
professionals and help make recommendations and decisions for tapering
medications or treatment selection according to the panelists
additionally pharmacists are also the ones who are planning treatment
pathways around insurance issues lee explained that she and other
pharmacists at her practice must often plan far in advance because certain
insurance companies are not always specific in what they are able to cover
or may not know which limited distribution specialty pharmacies carry
certain medications such as ruxolitinib ali echoed this point by
emphasizing his experiences when treating patients
“even coming up with treatments we do that all the time i have providers
come up to me almost daily and share a case with me and say ‘this is the
situation’ and every practice is different but that’s the direction we’re
heading in” ali explained during the discussion “so having a pharmacist on
the patient’s health care team to break everything down is extremely
important”
download issue pdf
download ris
articles in this issue
medical panelists credit africa studio stockadobecomblob expanding roles new approaches for pharmacists in managing graftvshost disease red blood cells credit ktsdesign stockadobecomblob addressing challenges when implementing bispecific antibodies in diverse settings lgbtqia couple holding hands credit nong stockadobecomblob enhancing cancer care sogi data collection for sexual and gender minority patients remains critical blood sample positive for multiple myeloma credit luchschenf stockadobecomblob operationalizing bispecific antibodies across academic and community oncology centers in hematologic malignancies woman with cancer credit africa studio stockadobecomblob end of ocm brings dropoff in valuebased care volume new questions pharmacist helping a patient credit yuri arcurspeopleimagescom stockadobecomblob breaking down silos in oncology care enhancing communication and education for improved patient outcomes health care provider and patient credit c davidspeopleimagescom stockadobecomblob the chemotherapist subcutaneous injection credit photobytawat stockadobecomblob pharmacy departmentdriven initiative to reduce subcutaneous daratumumab observation time older woman receiving chemotherapy credit seventyfour stockadobecomblob drug shortages in community oncology ensuring access to chemotherapy cll in blood credit drmicrobe stockadobecomblob covalent btk inhibitors a review of the evidence in chronic lymphocytic leukemia chemotherapy iv drip credit zlikovec stockadobecomblob addressing the ethical complications of drug shortages woman with cancer and her daughter credit africa studio stockadobecomblob sex and gender inequalities in oncology care and research persist patient receiving chemotherapy through iv credit denis stockadobecom blob navigating oncology drug shortages ethical frameworks and strategic management
recent videos
credit © anastasiia stockadobecomblob clinical perspectives on gprcdtargeted car tcell therapy for multiple myeloma lgbtqia pride credit lazyllama stockadobecom blob expert having conversations and practicing cultural competency with lgbtqia patients credit © анастасія стягайло stockadobecomblob breakthroughs in cutaneous malignancy treatments exploring innovations in asco data breast cancer treatment credit © siam stockadobecomblob innovations in breast cancer therapy key updates and clinical implications credit © dragana gordic stockadobecomblob enhancing qualityoflife care the vital role of pharmacists in supportive care during cancer treatment small cell lung cancer treatment credit © craftyimago stockadobecomblob exploring innovative targeted therapies for relapsed sclc navigating the complex landscape of cell and gene therapy challenges and solutionsblob navigating the complex landscape of cell and gene therapy challenges and solutions lymphoma opc asco hodgkin lymphomablob insights into the evolving landscape of hematology treatment car t cell therapy multiple myeloma credit © lusimila stockadobecomblob from research to practice new treatment modalities for patients with multiple myeloma paloma trial advances sc amivantamab lazertinib for advanced nsclc with egfr mutations to the first lineblob paloma trial advances sc amivantamab lazertinib for advanced nsclc with egfr mutations to the first line
related content
advertisement
man getting vaccinated by a woman both wearing masksblob
patients with cancer have unique considerations for influenza vaccination
samantha gorski pharmd candidate
july rd article
pharmacy focus oncology edition benefits of subcutaneous amivantamab for lung cancer treatmentblob
pharmacy focus oncology edition benefits of subcutaneous amivantamab for
lung cancer treatment
june th podcast
orange slice symbolizing vitamin c is eating the cut out piece on orange background credit cagkan stockadobecom blob
orange juice can aid absorption of iron
kennedy ferruggia assistant editor
july rd article
pharmacy focus oncology edition pharmacists pivotal role in driving clinical trial researchblob
pharmacy focus oncology edition pharmacists pivotal role in driving
clinical trial research
may th podcast
pharmacy students social determinants of health credit luckybusiness stockadobecomblob
experts social determinants of health should be as important as clinical
content in pharmacy curricula
ashley gallagher associate editor
july nd article
a doctor hands over a strip of pills to an elderly patient ensuring proper medication management credit sommersby stockadobecom blob
stay aware of common highalert medications
kathleen kenny pharmd rph
july nd article
related content
oncology
publications
clinical forum
advertisement
man getting vaccinated by a woman both wearing masksblob
patients with cancer have unique considerations for influenza vaccination
samantha gorski pharmd candidate
july rd article
pharmacy focus oncology edition benefits of subcutaneous amivantamab for lung cancer treatmentblob
pharmacy focus oncology edition benefits of subcutaneous amivantamab for
lung cancer treatment
june th podcast
orange slice symbolizing vitamin c is eating the cut out piece on orange background credit cagkan stockadobecom blob
orange juice can aid absorption of iron
kennedy ferruggia assistant editor
july rd article
pharmacy focus oncology edition pharmacists pivotal role in driving clinical trial researchblob
pharmacy focus oncology edition pharmacists pivotal role in driving
clinical trial research
may th podcast
pharmacy students social determinants of health credit luckybusiness stockadobecomblob
experts social determinants of health should be as important as clinical
content in pharmacy curricula
ashley gallagher associate editor
july nd article
a doctor hands over a strip of pills to an elderly patient ensuring proper medication management credit sommersby stockadobecom blob
stay aware of common highalert medications
kathleen kenny pharmd rph
july nd article
advertisement
recent content
blob teenage girl looking at herself in the mirror credit halfpoint stockadobecom analysis determines body dysmorphic disorder is the most common in adolescent girls blob rsv vaccine vial behind a lung ct scan pharmacists play key role in selecting best rsv vaccine for older adults blob man getting vaccinated by a woman both wearing masks patients with cancer have unique considerations for influenza vaccination blob diabetes meal replacement credit jagcz stockadobecom intermittent fasting and meal replacements improved shortterm glycemia
view more recent content
advertisement
consent preferences
about us
clinical forums
advertise
contact us
editorial staff
privacy policy
terms conditions
do not sell my information
contact info
commerce drive
cranbury nj
tel
blob blob
© mjh life sciences
all rights reserved
- text: "takeda commits m for chance to bring immunotherapy to alzheimer’s disease medcity news\n\n \n\n twitter\n facebook\n linkedin\n rss\n subscribe via email\n\n newsletter signup\n send tipsmailto\n\nopen navigation\n\nmedcity news\n\ntoggle search\n\n news\n health tech\n biopharma\n devices diagnostics\n consumer employer\n contributors\n medcity influencers\n medcitizens\n events\n invest\n invest digital health\n engage at hlth\n podcasts\n research\n newsletters\n\n newsletter signup\n send tipsmailto\n\n twitter\n facebook\n linkedin\n rss\n subscribe via email\n\n search for search\n\nbiopharma pharma\n\ntakeda commits m for chance to bring immunotherapy to alzheimer’s disease\n\n\ntakeda pharmaceutical has secured an option on an alzheimer’s disease immunotherapy from ac immune that is on track to report its first phase data later this quarter exercising the option would make takeda responsible for phase testing of the therapy putting ac immune in line for up to billion in milestone payments\n\nby frank vinluan on may \n\nshare\n\nshare options\n\nshare a link too this article\n\n copy link copy link\n emailmailtobody\n facebook\n linkedin\n x\n\n \n\nalzheimer’s disease can be treated with antibody drugs that reduce levels of amyloid beta protein in the brain clinicalstage biotech company ac immune is developing a novel therapy that sparks the immune system to clear away amyloid plaque and takeda pharmaceutical sees enough promise in this approach to commit million for the opportunity to pick up this experimental therapy\n\nthe ac immune drug codenamed aci is currently being evaluated in the phase portion of a phase b study under the deal terms announced monday takeda’s upfront payment gives it an exclusive option to license global rights to this immunotherapy\n\naci is an immunogenic peptide that is presented to the immune system’s b cells in a way that mimics the pathological form of amyloid beta this presentation is intended to spark activity from antibodies that bind to pathological forms of the protein in preclinical research lausanne switzerlandbased ac immune has reported that the drug led to higher blood levels of immunoglobulin g antibodies that were associated with reduction in amyloid plaque in tests in monkeys ac immune reported a favorable safety profile for the drug\n\nsponsored content\n\n \n\n integrated enrollment platforms and consumer assistance centers the strongest advantage for statebased exchanges\n\nin the everevolving landscape of statebased health insurance exchanges the convergence of technology and customer service is reshaping how these exchanges operate the increasing advent of automation and artificial intelligence ai is rapidly dismantling the traditional business model that relies on the siloing of technology and customer service centers\n\nby shankar srinivasan cofounder and general manager getinsured and jason sparks vp of project management and implementation getinsured\n\nac immune is responsible for completing the placebocontrolled phase b study which is evaluating for aci in patients with early alzheimer’s the study is also testing the immunotherapy as a treatment for patients with down syndrome under the takeda agreement the japanese pharmaceutical giant may exercise its option after it receives predefined clinical data on the first three alzheimer’s patient cohorts from the ongoing study ac immune said in a regulatory filing the first phase data on amyloid plaque reduction after six months of treatment will be reported in the current quarter potentially paving the way for phase testing ac immune said monday in its report of financial results for the first quarter of \n\n“we believe the maximum impact of aci can best be realized by partnering with takeda at this critical juncture in its development which will help us move rapidly into phase ” ac immune ceo andrea pfeifer said in a prepared statement “this agreement allows us to leverage the developmental expertise strategic vision and financial capacity of an accomplished organization that has demonstrated its ability to execute the type of comprehensive global program required for phase trials in alzheimer’s disease while allowing us to focus on completing phase b development and accelerating our efforts to replicate this success with enhanced funding for our earlystage pipeline”\n\nupdated to add the following three paragraphs with analyst commentary an antiamyloid beta or “abeta” approach already has partial validation from the fda approval of the amyloid plaque antibody busting drug leqemb from eisai as well as donanemab an eli lilly drug still under regulatory review leerink partners analyst marc goodman wrote in a march research note but safety could be a key differentiator for an alzheimer’s immunotherapy antibody drugs developed for the disease introduce the risk of amyloidrelating imaging abnormalities aria brain bleeding and swelling that is a known adverse effect of this class of therapies an earlier formulation of ac immune’s therapy yielded mixed phase data while the results showed favorable safety with no signs of aria the immune response was “suboptimal” goodman said\n\naci is a new formulation incorporating changes intended to boost the immune response goodman said translation of immune response to amyloid beta clearance andor clinical benefit remains a key question also active immunotherapy may take longer to show an effect compared with antibody drugs he added while those questions remain unanswered so far the takeda deal is positive news for ac immune goodman wrote in a monday research note\n\nsponsored post\n\n \n\n what’s keeping healthcare cios up at night how health systems automate routine phone calls to improve workforce effectiveness and reduce agent burnout\n\nwith hospitals struggling to retain staff and valuebased care shrinking healthcare revenues health systems must look to technology resources to become more efficient without losing sight of patient care or staff support\n\n“once again management has executed on a significant partnership with a big pharma company to develop an asset that has received minimal value in the stock confirming our longterm thesis that this management team can leverage its two proprietary drug discovery platforms and diversified pipeline to drive value” goodman said\n\nthe agreement makes ac immune eligible for up to billion in milestone payments which includes an option exercise fee in the lowtomidhundred millions of dollars according to the regulatory filing after exercising that option takeda will be responsible for clinical development of the alzheimer’s drug takeda will also handle regulatory submissions as well as commercialization if the drug is approved ac immune will receive royalties from takeda’s sales of the immunotherapy\n\naci would give takeda another opportunity to address alzheimer’s but with a drug candidate that has been derisked with clinical data the company previously partnered with denali therapeutics on the development of an antibody engineered to penetrate the brain to hit and activate a target called trem last august the two companies announced they would discontinue clinical development of this alzheimer’s drug after safety signals emerged in phase testing takeda also has a research collaboration with cure network dolby acceleration partners focused on developing small molecules that target tau in alzheimer’s and other brain disorders\n\nac immune has other alliances in alzheimer’s its antitau immunotherapy aci is currently in midstage clinical development under a partnership with johnson johnson subsidiary janssen pharmaceuticals a tau aggregation inhibitor is in preclinical development under a partnership with eli lilly two ac immune antibodies semorinemab and crenezumab were partnered with roche’s genentech division but after disappointing clinical trial results genentech terminated the alliance early this year returning to ac immune rights to both antibodies\n\npublic domain by flickr user scitechtrend\n\ntopics\n\n\n ac immune\n alzheimers disease\n clinical trials\n deals\n japan\n switzerland\n takeda pharmaceutical\n\nmedcity news daily newsletter\n\n\n sign up and get the latest news in your inbox\n\nenter your email address subscribe now\n\nwe will never sell or share your information without your consent see our privacy policy\n\nmore from medcity news\n\n\nmedcity influencers\n\n \n\n restoring public trust in the biopharma industry the role of advanced analytics\n\nby ryan calsbeek and haider nazar\n\nmedcity influencers\n\n \n\n the right to privacy — what a novel concept\n\nby chris bowen\n\nmedcity influencers\n\n \n\n patients want personalized digital experiences could a modular back end help\n\nby luiz cieslak\n\nhealth tech payers\n\n \n\n ncpa providers file lawsuit against uhg over change healthcare cyberattack\n\nby marissa plescia\n\n \n\nhealth it\n\n best practices in achieving revenue cycle excellence\_\n\ndiscover the best practices in revenue cycle management to enhance financial health and streamline administrative processes in healthcare\n\nby greenway health\n\nrecommended\n\n\nsponsored post\n\n streamlining healthcare how technology is removing friction for providers\n\n annual benefit consultant report offers window into selfinsured employers’ benefit priorities including emphasis on care navigation\n\nsponsored post\n\n hospitals and health system executives say change management is essential for innovation\n\n \n\nsponsored content\n\n the impact brands empowering wellness through natural and holistic solutions\n\nin an era of escalating healthcare costs and a growing preference for natural holistic approaches to health the impact brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means\n\nby impact brands\n\nmedcity news daily newsletter\n\n\n sign up and get the latest news in your inbox\n\nenter your email address subscribe now\n\nwe will never sell or share your information without your consent see our privacy policy\n\n advertise\n about\n newsletter\n\nour sites\n\n\n above the law\n\n how appealing\n\n breaking defense\n\n breaking energy\n\n breaking gov\n\n deal breaker\n\n fashionista\n\n med city news\n\n© breaking media inc all rights reserved registration or use of this site constitutes acceptance of our terms of service and privacy policy\n\n dmca compliant dmca compliance information for abovethelawcom\n\n \n\n \n\n×\n\nthis website uses cookies to enhance user experience and to analyze performance and traffic on our website we also share information about your use of our site with our social media advertising and analytics partners\n\ndo not sell my personal information accept cookies\n\n company logo\n\ndo not sell my personal information\n\n\nwhen you visit our website we store cookies on your browser to collect information the information collected might relate to you your preferences or your device and is mostly used to make the site work as you expect it to and to provide a more personalized web experience however you can choose not to allow certain types of cookies which may impact your experience of the site and the services we are able to offer click on the different category headings to find out more and change our default settings according to your preference you cannot optout of our first party strictly necessary cookies as they are deployed in order to ensure the proper functioning of our website such as prompting the cookie banner and remembering your settings to log into your account to redirect you when you log out etc for more information about the first and third party cookies used please follow this link \nmore information\n\nallow all\n\n manage consent preferences\n\n strictly necessary cookies\n\nalways active\n\nthese cookies are necessary for the website to function and cannot be switched off in our systems they are usually only set in response to actions made by you which amount to a request for services such as setting your privacy preferences logging in or filling in forms you can set your browser to block or alert you about these cookies but some parts of the site will not then work these cookies do not store any personally identifiable information\n\n sale of personal data\n\n sale of personal data\n\nunder the california consumer privacy act you have the right to optout of the sale of your personal information to third parties these cookies collect information for analytics and to personalize your experience with targeted ads you may exercise your right to opt out of the sale of personal information by using this toggle switch if you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties additionally you may contact our legal department for further clarification about your rights as a california consumer by using this exercise my rights link \n \nif you have enabled privacy controls on your browser such as a plugin we have to take that as a valid request to optout therefore we would not be able to track your activity through the web this may affect our ability to personalize ads according to your preferences\n\n performance cookies\n \n switch label label\n \n these cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site they help us to know which pages are the most and least popular and see how visitors move around the site all information these cookies collect is aggregated and therefore anonymous if you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance\n \n\n targeting cookies\n \n switch label label\n \n these cookies may be set through our site by our advertising partners they may be used by those companies to build a profile of your interests and show you relevant adverts on other sites they do not store directly personal information but are based on uniquely identifying your browser and internet device if you do not allow these cookies you will experience less targeted advertising\n \n\n cookie list\n\n \n\nclear\n\n checkbox label label\n\napply cancel\n\nconsent leginterest\n\n checkbox label label\n\n checkbox label label\n\n checkbox label label\n\nconfirm my choices\n\n powered by onetrust"
- text: "finanzennet seite nicht gefunden\n\n blob \n\ndax est msciw dow nas bitcoin euro öl gold \n\n finanzennet online broker online broker\n\nbeliebte suche\n\ndax ölpreis euro dollar bitcoin euro goldpreis\n\nmeistgesucht\n\ntesla acxt tesla zur watchlist hinzufügen nvidia nvidia zur watchlist hinzufügen varta atgj varta zur watchlist hinzufügen deutsche bank deutsche bank zur watchlist hinzufügen rheinmetall rheinmetall zur watchlist hinzufügen crowdstrike apkr crowdstrike zur watchlist hinzufügen alphabet a ex google ayf alphabet a ex google zur watchlist hinzufügen sap sap zur watchlist hinzufügen lvmh moet hennessy louis vuitton lvmh moet hennessy louis vuitton zur watchlist hinzufügen tui tuag tui zur watchlist hinzufügen porsche pag porsche zur watchlist hinzufügen amazon amazon zur watchlist hinzufügen apple apple zur watchlist hinzufügen bayer bay bayer zur watchlist hinzufügen nel asa ab nel asa zur watchlist hinzufügen\n\nalle aktien für euro zzgl spreads handeln mit finanzennet zero hier informieren\n\nheute im fokus\n\n uhr dax schließt klar im minus rheinmetallzahlen überzeugen porsche mit gewinnrückgang deutsche bank mit verlust tesla alphabet crowdstrike tmtg visa lvmh im fokus\n\ntop news\n\n uhr börse new york nasdaq zeigt sich leichter \n\n uhr schwache performance in new york sp notiert im minus \n\nsuche\n\nzero depot finanzennet zero depot finanzennet zero trading finanzennet zero zero depot finanzennet zero trading finanzennet zero krypto kaufen etfsparplan finanzennet oskar anmeldenanmelden\n\nfavoriten\n\n \n\nseite zu favoriten hinzufügen\n\n \n\nwird geladen \n\n \n\ngeben sie einen neuen namen \nfür diesen favoriten ein\n\n \n\nverwerfen speichern\n\nlogin\n\n \n\noder\n\n \n\nneu weiter mit google\n\n \n\nneu auf finanzennet\n\nkostenfrei registrieren und vorteile nutzen\n\n \n\nübersicht wertpapierdepots musterdepots watchlists meine news newsletter forum trading desk apps social media podcasts\n\n \n\nprofil\n\nübersicht wertpapierdepots musterdepots watchlists meine news newsletter forum trading desk apps social media podcasts\n\n \n\nprofil logout\n\n depot eröffnen depot eröffnen\n zerotrading zerotrading\n etfsparplan etfsparplan\n login login\n übersicht\n wertpapierdepots\n musterdepots\n watchlists\n meine news\n newsletter\n forum\n trading desk\n apps\n social media\n podcasts\n profil\n logout\n\n aktien\n aktienübersicht\n aktiensuche\n meistgesuchte aktien\n top flop dax\n top deutschland\n top ausland\n branchen\n ipos neuemissionen\n chartanalyse\n specials\n advertorials\n pennystocks\n videos\n trading desk\n realtimekurse\n daxaktien\n mdaxaktien\n sdaxaktien\n tecdaxaktien\n dow jonesaktien\n euro stoxx aktien\n smiaktien\n atxaktien\n weitere aktien deutschland\n weitere aktien usa\n termine\n übersicht der termine\n hauptversammlung\n quartalszahlen\n wirtschaftskalender\n dividendenausschüttung\n insiderdaten\n anlagetrends\n kiaktien\n drohnen\n chatgpt profiteure\n cannabismarihuana\n solaraktien\n gamingaktien\n vermögenswirksame leistungen\n trading idee\n finanzennet watchlists neu\n dividenden\n top dividendenrendite\n dividendentermine\n brokervergleich\n onlinebrokervergleich\n cfdbrokervergleich\n roboadvisorvergleich\n kryptobrokervergleich\n kryptobörsenvergleich\n aktienratgeber\n aktien kaufen verkaufen\n aktienhandel mit system\n aktien als geschenk\n selection\n deutschlands bestes girokonto mit zinsen pa neu\n \n news\n newsübersicht\n unternehmensmeldungen\n heute im fokus\n expertenkolumnen\n nachrichten aus deutschland\n nachrichten aus usa\n nachrichten weitere länder\n news standardwerte\n news nebenwerte\n konjunkturdaten\n webinare\n kursbewegungen\n videos\n newsletter\n newssuche\n aktiennews\n anleihennews\n cfdnews\n devisennews\n etfnews\n fondsnews\n geld karriere lifestyle\n private finanzennews\n rohstoffenews\n zertifikatenews\n zinsennews\n kryptowährungennews\n news zu nachhaltigkeit\n indexnews\n daxnews\n dow jonesnews\n mdaxnews\n eurostoxxnews\n tecdaxnews\n nasdaqnews\n sp news\n atxnews\n sminews\n nikkei news\n analysen\n daxanalysen\n analysen nach indizes\n chartanalyse\n analysen nach ländern\n zum researchtool\n rubriken\n redaktion finanzennet\n aktie im fokus\n adhocmeldungen\n investoren news\n themen\n toprankings\n expertenempfehlung zum verkauf\n expertenempfehlung zum kauf\n topnews\n \n table classtabletbody classtabletbodytr classtabletrtd classtabletd paddingverticala classdisplayblock marginbottom hrefnachrichtaktienboersenewyorknasdaqzeigtsichleichterimg classimg imgstretch src width height alt loadinglazy aspana hrefnachrichtaktienboersenewyorknasdaqzeigtsichleichterbörse new york nasdaq zeigt sich leichteraspantdtrtr classtabletrtd classtabletd paddingverticalspana hrefnachrichtaktienschwacheperformanceinnewyorkspnotiertimminusschwache performance in new york sampp notiert im minusaspantdtrtr classtabletrtd classtabletd paddingverticalspana hrefnachrichtaktienboersenewyorkinrotdowjonesinderverlustzonebörse new york in rot dow jones in der verlustzoneaspantdtrtr classtabletrtd classtabletd paddingverticalspana hrefnachrichtaktienschwacheperformanceinnewyorknasdaqcompositeammittwochmittagleichterschwache performance in new york nasdaq composite am mittwochmittag leichteraspantdtrtr classtabletrtd classtabletd paddingverticalspana hrefnachrichtaktienguccimutterkeringmeldetumsatzundgewinnrueckgangimerstenhalbjahrkering meldet umsatz und gewinnrückgang im ersten halbjahraspantdtrtbodytable\n \n alle topnews\n indizes\n indexübersicht\n weltindizes\n chartübersicht\n länder\n emerging markets\n futures\n märkte\n börsenfeiertage\n wichtige indizes\n dax\n mdax\n sdax\n tecdax\n dow jones\n sp \n nasdaq \n euro stoxx \n smi\n atx\n cac \n nikkei \n index listen\n dax\n mdax\n sdax\n tecdax\n dow jones\n sp \n nasdaq \n eurostoxx\n smi\n atx\n cac \n nikkei \n topflop listen\n dax\n mdax\n sdax\n tecdax\n eurostoxx\n smi\n atx\n sp \n dow jones\n nasdaq \n cac \n realtimekurse\n realtimeübersicht\n daxrealtime\n tecdaxrealtime\n mdaxrealtime\n euro stoxx realtime\n dow jones realtime\n nasdaq realtime\n sp realtime\n nikkei realtime\n atxrealtime\n fonds\n fondsübersicht\n topperformer\n fondsgesellschaften\n nachhaltige investments\n anlagedepot neu\n fondssuche\n aktienfonds\n rentenfonds\n immobilienfonds\n geldmarktfonds\n rohstofffonds\n mischfonds\n sonstige fonds\n nachhaltige fonds\n fondsregionen\n fonds deutschland\n fonds europa\n fonds usa\n fonds welt\n fonds news\n interviews\n hedgefonds\n kvgnews\n nachhaltige investments\n fonds mit fngsiegel\n geldanlage mit ökofonds\n specials\n german fund champions \n \n etfs\n etfübersicht\n topperformer etfs\n etfnews\n etfkursbewegungen\n etflexikon\n etcübersicht\n anlagedepot neu\n etfsuche\n msci worldetfs\n daxetfs\n aktienetfs\n anleihenetfs\n rohstoffetfs\n geldmarktetfs\n etfsparplan\n beste sparpläne tipps tricks\n beliebte sparplanetfs\n etfsparplanvergleich\n etfratgeber\n etf kaufen\n daxetfs im test\n mdaxetfs im test\n msci worldetfs im test\n goldetfs kaufen\n roboadvisorvergleich\n roboadvisor im test\n investieren mit oskar\n geldanlage für kinder\n etfsparen für kinder\n börsenspielvergleich\n specials\n wissenswertes über etfs\n etfs intelligent handeln\n german fund champions \n \n zertifikate\n zertifikateübersicht\n topbasiswerte\n top zertifikate umsätze\n produktnews\n news von emittenten\n emittenten\n video produkterklärungen\n derivate newsletter\n tradingdepot\n zertifikatesuche\n airbagzertifikate\n aktienanleihen\n alphazertifikate\n basketzertifikate\n bonuszertifikate\n discountzertifikate\n expresszertifikate\n index trackerzertifikate\n garantiezertifikate\n outperformancezertifikate\n sprintzertifikate\n kioptimierte hebelproduktsuche beta\n tools\n zertifikatematrix\n emittentenmatrix\n knockoutmap\n top aktienanleihen\n top bonuszertifikate\n top discountzertifikate\n basiswertsuche\n indizes\n aktien\n baskets\n währungen\n rohstoffe\n zinsen anleihen\n sonstige basiswerte\n wissen\n aktienanleihen\n bonuszertifikate\n discountzertifikate\n expresszertifikate\n garantiezertifikate\n goldzertifikate\n indexzertifikate\n outperformancezertifikate\n ölzertifikate\n rollingdiscountzertifikate\n twinwinzertifikate\n neuemissionen\n letzte neuemissionen\n intradayemissionen\n discountzertifikate\n bonuszertifikate\n sonstige\n specials\n zertifikate\n aktienanleihen\n rohstoffe\n \n hebelprodukte\n hebelprodukteübersicht\n meistgeklickte basiswerte\n os mit top trades\n ko mit top trades\n emittenten\n produktnews\n news von emittenten\n derivate newsletter\n tradingdepot\n hebelproduktesuche\n optionsscheine\n knockoutzertifikate\n inlineoptionsscheine\n exotische optionsscheine\n faktoroptionsscheine\n kioptimierte hebelproduktsuche beta\n tools\n zertifikatematrix\n emittentenmatrix\n knockoutmap\n top aktienanleihen\n top bonuszertifikate\n top discountzertifikate\n basiswertsuche\n indizes\n aktien\n baskets\n währungen\n rohstoffe\n zinsen anleihen\n sonstige basiswerte\n wissen\n faktoroptionsscheine\n goldzertifikate\n hebelzertifikate\n knockoutzertifikate\n mini futures\n optionsscheine\n ölzertifikate\n turbozertifikate\n neuemissionen\n letzte neuemissionen\n intradayneuemissionen\n optionsscheine\n knockouts\n specials\n zertifikate\n aktienanleihen\n rohstoffe\n cfds\n was sind cfds\n volatile trading instrumente\n cfd brokervergleich\n \n anleihen\n anleihenübersicht\n top performer\n meistgesuchte anleihen\n neuemissionen\n anleiheemittenten\n anleihenrating\n anleihensuche\n europäische staatsanleihen\n unternehmensanleihen\n bundesanleihen\n usstaatsanleihen\n anleihen mit aaarating\n investmentgrade anleihen\n junk bonds high yield\n rendite über \n zerobonds\n wissen\n bundesanleihen\n emerging marketsanleihen\n eurostaatsanleihen\n genussscheine\n jumbo pfandbriefe\n währungsanleihen\n unternehmensanleihen\n niedrigzinsanleihen\n anleihen mit variablem zins\n weitere anleihetypen\n sonderformen\n zinsen\n zinsstrukturkurven\n leitzins\n libor\n euribor\n zinstermine\n historische leitzinsen\n leitzins news\n anleihenratgeber\n anleihen kaufen\n \n rohstoffe\n rohstoffeübersicht\n realtimekurse\n rohstoffcharts\n basiswissen\n rohstoffzertifikate\n wichtige rohstoffe\n gold\n silber\n ölpreis\n platin\n palladium\n weizen\n aluminium\n erdgas\n gold kaufen\n so funktioniert der goldkauf\n goldmünzen kaufen\n goldbarren kaufen\n american eagle\n britannia\n krügerrand\n maple leaf\n silber kaufen\n so funktioniert der silberkauf\n silbermünzen kaufen\n silberbarren kaufen\n forward curve\n edelmetalle\n energierohstoffe\n industriemetalle\n agrarrohstoffe\n etcs\n einzelner rohstoff\n rohstoffkörbe\n specials\n rohstoffe\n cfds\n was sind cfds\n cfdbrokervergleich\n \n krypto\n kryptoübersicht\n kryptonews\n kryptotrading tipp\n wichtige kryptowährungen\n bitcoin kurs\n ethereum kurs\n tether kurs\n binance coin kurs\n monero kurs\n ripple kurs\n avalanche kurs\n cardano kurs\n uniswap kurs\n polygon kurs\n litecoin kurs\n solana kurs\n polkadot kurs\n chainlink kurs\n kryptowährungen kaufen\n bitcoin kaufen\n ethereum kaufen\n tether kaufen\n bitcoin cash kaufen\n monero kaufen\n ripple kaufen\n avalanche kaufen\n cardano kaufen\n uniswap kaufen\n polygon kaufen\n litecoin kaufen\n solana kaufen\n polkadot kaufen\n chainlink kaufen\n kryptoratgeber\n kryptobörsenvergleich\n kryptobrokervergleich\n investieren in die blockchain\n bitcoin steuern\n nft kaufen\n nftetf kaufen\n cfds\n was sind cfds\n cfdbrokervergleich\n \n devisen\n devisenübersicht\n realtimekurse\n crossrates\n tipps zum devisenhandel\n wichtige devisenpaare\n eurodollar\n eurofranken\n europfund\n türkische lira\n eurozloty\n eurorussische rubel\n eurobaht\n eurotschechische krone\n währungsrechner\n eurofranken\n eurodollar\n europfund\n eurotürkische lira\n eurozloty\n eurorussische rubel\n eurobaht\n eurotschechische krone\n kryptowährungen\n bitcoin\n ethereum\n ripple\n bitcoin cash\n litecoin\n iota\n diem\n neo\n kryptobroker vergleich\n bitcoin kaufen\n bitcoin cash kaufen\n diem kaufen\n ethereum kaufen\n iota kaufen\n neo kaufen\n kryptobörsen vergleich\n kryptowährungshandel\n ratgeber kryptowährungen\n cfds\n was sind cfds\n cfdbrokervergleich\n \n ratgeber\n unsere empfehlungen\n top unternehmen\n brutto netto rechner\n etfsparplan\n msci worldetf\n aktien kaufen\n cfdhandel\n cannabisaktien kaufen\n forextrading\n small caps\n geldanlage\n onlinedepot eröffnen\n geldanlage\n sparen für kinder\n öl handeln\n fonds kaufen\n anleihen kaufen\n optionsscheine\n kupfer kaufen\n gold kaufen\n goldshop\n etfs fonds und zertifikate\n etfs kaufen\n dow jonesetfs\n goldetfs\n dividendenfonds\n knockoutzertifikate\n goldzertifikate\n faktoroptionsscheine\n alternative investments\n kryptowährungen\n bitcoin kaufen\n ethereum kaufen\n ripple kaufen\n diem kaufen\n kryptobrokervergleich\n kryptobörsenvergleich\n konto kredit\n tagesgeldvergleich\n festgeldvergleich\n kreditkartenvergleich\n ratenkredit\n girokontovergleich\n onlinebanking\n broker depots\n roboadvisorvergleich\n onlinebrokervergleich\n oskar im test\n versicherung vorsorge\n kfzversicherung\n haftpflichtversicherung\n hausratversicherung\n riesterrente\n vermögenswirksame leistungen\n betriebsrente\n youtube\n etfsparplan einfach erklärt\n etfauswahl\n aktien kaufen in schritten\n die größten fehler beim aktienkauf\n geldanlagetipps\n \n\nsuche\n\nbeliebte suche\n\ndax ölpreis euro dollar bitcoin euro goldpreis\n\nmeistgesucht\n\ntesla acxt tesla zur watchlist hinzufügen nvidia nvidia zur watchlist hinzufügen varta atgj varta zur watchlist hinzufügen deutsche bank deutsche bank zur watchlist hinzufügen rheinmetall rheinmetall zur watchlist hinzufügen crowdstrike apkr crowdstrike zur watchlist hinzufügen alphabet a ex google ayf alphabet a ex google zur watchlist hinzufügen sap sap zur watchlist hinzufügen lvmh moet hennessy louis vuitton lvmh moet hennessy louis vuitton zur watchlist hinzufügen tui tuag tui zur watchlist hinzufügen porsche pag porsche zur watchlist hinzufügen amazon amazon zur watchlist hinzufügen apple apple zur watchlist hinzufügen bayer bay bayer zur watchlist hinzufügen nel asa ab nel asa zur watchlist hinzufügen\n\nalle aktien für euro zzgl spreads handeln mit finanzennet zero hier informieren\n\nsuche\n\n home home\n aktien aktien\n perseus therapeutics announces development of tslp antibody for prevention of hair loss in cancer patients and treatment of inflammatory diseases with wellknown cro partner\n\nperseus therapeutics announces development of tslp antibody for prevention of hair loss in cancer patients and treatment of inflammatory diseases with wellknown cro partner\n\n\n uhr\n\n \n\nwerbung\n\nnew york may prnewswire perseus therapeutics a pioneering biopharmaceutical company based in new york city is proud to announce the development of a novel thymic stromal lymphopoietin tslp antibody aimed at preventing hair loss in cancer patients and treating a range of inflammatory diseases including asthma\n\n pegasus horse next to the words perseus therapeutics inc\n\ntslp antibodies have recently gained significant attention in the medical and pharmaceutical communities these antibodies have shown potential in addressing various inflammatory and allergic conditions driven by their promising efficacy data and the unmet medical needs they aim to fulfill\n\nseveral companies and research groups are actively exploring tslp antibodies with notable developments including\n\n astrazeneca and amgen have developed tezepelumab the firstinclass antitslp monoclonal antibody approved for severe asthma treatment\n johnson johnson acquired proteologix to access its bispecific antibody targeting tslp and il\n blackstone has launched uniquity to advance mercks phase high potency tslp antibody\n innovent biologics is conducting a phase i study on ibi a dualfunction antibody targeting both ilrα and tslp\n sanofi and regeneron are developing sar a novel biologic targeting both tslp and il for asthma\n teva pharmaceuticals and biolojic design\_have entered into an exclusive license agreement to develop bispecific antibodies targeting tslp and il\n gsk\_recently acquired aiolos bio for billion upfront to enhance its respiratory biologics portfolio with aio a phase longacting antitslp monoclonal antibody\n\nthese strategic moves underscore the growing interest in tslp antibodies for treating a wide range of inflammatory and allergic conditions perseus therapeutics is poised to contribute to this dynamic field with its innovative approach to preventing hair loss in cancer patients a common and distressing side effect of cancer treatments and addressing other inflammatory diseases\n\nperseus therapeutics is committed to advancing the science of tslp antibodies to meet critical unmet medical needs said joseph hernandez chairman and founder of perseus therapeutics our work aims not only to improve the quality of life for cancer patients by preventing hair loss but also to provide effective treatments for various inflammatory conditions\n\nfor more information about perseus therapeutics and its pipeline of innovative therapies please visit or contact filecconvertwordtohtmlprimarycontentdownloadpath\n\nabout perseus therapeutics inc \nperseus therapeutics is a duke university spinout biopharmaceutical company dedicated to developing innovative therapies for cancer patients and those suffering from inflammatory diseases based in new york city perseus therapeutics is at the forefront of antibody research and development striving to bring new hope and improved outcomes to patients worldwide\n\n cision view original content to download multimedia\n\nsource perseus therapeutics inc\n\netf und aktiensparpläne ohne ordergebühren zzgl spreads\n\nin eigener sache\n\nvermögensaufbau mit sparplänen kann so einfach sein wechsle zu finanzennet zero und zahle ab sofort keine ordergebühren mehr nur marktübliche spreads\n\ninformiere dich jetzt und nutze zerokonditionen für deine sparpläne\n\n \n\ndas könnte sie auch interessieren\n\nempfohlen von \n\nnewssuche\n\n\nsuche\n\nwerbung\n\n tradingnews\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletd paddinghorizontaldiv classlogohvb titleunicredit bank agdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titletagesausblick für anleger reagieren enttäuscht auf techzahlen ifo nordex und usarbeitsmarktdaten stehen antagesausblick für anleger reagieren enttäuscht auf techzahlen ifo nordex und usarbeitsmarktdaten stehen anatdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogosocgen titlesociete generaledivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlemehr diversifikation mit gleichgewichteten indizesmehr diversifikation mit gleichgewichteten indizesatdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogohsbc titlehsbcdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlealphabettochter google steigert werbeerlöse – aktie dennoch deutlich im minusalphabettochter google steigert werbeerlöse – aktie dennoch deutlich im minusatdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogoxtb titlextb xtrade brokersdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titletradingidee des tages silver tradingidee des tages silver atdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogoubs titleubsdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlesap se – neues allzeithochsap se – neues allzeithochatdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogowhs titlewh selfinvestdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlebullische fortsetzung im goldfuture möglichbullische fortsetzung im goldfuture möglichatdtrtr classtabletrtd classtabletd paddinghorizontaldiv classlogowgz titledz bankdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titledax gd und slow stochastik liefern kaufsignaledax gd und slow stochastik liefern kaufsignaleatdtrtbodytable\n\nalle tradingnews alle tradingnews\n\nwerbung\n\n investmentnews\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletddiv classlogowikifolio titlewikifoliodivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlebyebye big tech hello small capsbyebye big tech hello small capsatdtrtr classtabletrtd classtabletddiv classlogobitcapfavico titlebit capitaldivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlebit capital welche techaktien sind gerade wirklich günstigbit capital welche techaktien sind gerade wirklich günstigatdtrtr classtabletrtd classtabletddiv classlogofvsfavico titleflossbach von storchdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlemultiasset auf den abgesang folgt das comebackmultiasset auf den abgesang folgt das comebackatdtrtr classtabletrtd classtabletddiv classlogoetcgroup titleetc groupdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlebitcoin schießt inmitten eines globalen itausfalls in die höhe etc group crypto market compass juli bitcoin schießt inmitten eines globalen itausfalls in die höhe etc group crypto market compass juli atdtrtr classtabletrtd classtabletddiv classlogoetoro titleetorodivtdtd classtabletd tabletdlineclampa hrefnachrichtaktienmonetarisierungvonkidasgrossepotenzialunddiehohenerwartungen titlemonetarisierung von ki das große potenzial und die hohen erwartungenmonetarisierung von ki das große potenzial und die hohen erwartungenatdtrtr classtabletrtd classtabletddiv classlogoophirum titleophirumdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlegoldsparpläne sind immer eine gute wahl jetzt mehr denn jegoldsparpläne sind immer eine gute wahl jetzt mehr denn jeatdtrtr classtabletrtd classtabletddiv classlogozerofavico titlezerodivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlekryptos handeln bei finanzennet zerokryptos handeln bei finanzennet zeroatdtrtr classtabletrtd classtabletddiv classlogowiwinfavico titlewiwindivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlejetzt in elektromobilität investieren und p a maximal erwartete rendite sichernjetzt in elektromobilität investieren und p a maximal erwartete rendite sichernatdtrtr classtabletrtd classtabletddiv classlogodda titledeutsche digital assetsdivtdtd classtabletd tabletdlineclampa href targetblank relnofollow noopener titlevon den top krypto assets in einem etp profitieren dda crypto select etpvon den top krypto assets in einem etp profitieren dda crypto select etpatdtrtr classtabletrtd classtabletddiv classlogooskarfavico titleoskardivtdtd classtabletd tabletdlineclampa href titledieses geldgeschenk bringt ihnen bis zu eurodieses geldgeschenk bringt ihnen bis zu euroatdtrtbodytable\n\nalle investmentnews alle investmentnews\n\nwerbung\n\n terminhighlights\n\nteilnehmenthomas vittnerwie ich endlich beim trading erfolgreich wurde\n\nteilnehmenroland jegenneue volumenfeatures effektiv in den usmärkten nutzen\n\nteilnehmenmarcel ruthwarum jetzt die richtige zeit ist ein depot bei wh selfinvest zu eröffnen\n\nwerbung\n\nneue funktionen als erstes nutzen\n\nsie nutzen finanzennet regelmäßig dann nutzen sie jetzt neue funktionen als erstes\n\nhier informieren hier informieren\n\n börse stuttgart anlegerclub\n\n \n\n entdecke die app die deine finanzen revolutioniert – jetzt tradespot herunterladen die app die deine finanzen revolutioniert – jetzt tradespot herunterladen\n\n\n\nnews von die welt\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletda href targetblank relnofollow noopeneralphabets youtubeproblem und der wasserstoffschaufelherstelleratdtrtr classtabletrtd classtabletda href targetblank relnofollow noopener„wir bauen den leerstand von morgen“ – was ist an der mahnung dranatdtrtr classtabletrtd classtabletda href targetblank relnofollow noopenerrüstungsaktien kaufen – tipps für anfängeratdtrtr classtabletrtd classtabletda href targetblank relnofollow noopenerteslas elonmuskproblem und der erste kigesteuerte etfatdtrtr classtabletrtd classtabletda href targetblank relnofollow noopenerbis zu prozent kurspotenzial – mit diesen aktien profitieren sie von einem harrissiegatdtrtbodytable\n\nheute im fokus\n\n\ndax schließt klar im minus rheinmetallzahlen überzeugen porsche mit gewinnrückgang deutsche bank mit verlust tesla alphabet crowdstrike tmtg visa lvmh im fokus erhöht prognose hochtief steigert erneut gewinn deutlich apple kurszielanhebung durch jpmorgan tmobilekonkurrent att gewinnt hunderttausende neukunden texas instruments beruhigt mit ausblick umsatz und gewinnanstieg erwartet aireuropakauf durch iag eu bleibt skeptisch totalenergies investiert in rwewindpark in den niederlanden\n\nnachrichten\n\n\naktien\n\nalle\n\nroundup berlin und london wollen militärzusammenarbeit vertiefen\n\nwdhaktien wien schluss atx marginal im minus\n\naktien wien schluss atx im minus rhi nach zahlen schwach\n\nrenault so profitabel wie noch nie\n\nrady childrens hospital teamsters end ulp strike demand hospital return to negotiations\n\nsecond quarter turnover \n\nausblick ford motor öffnet die bücher zum abgelaufenen quartal\n\neqscms bp plc release of a capital market information\n\ntoprankings\n\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titlemdax gewinner und verlierer die top flop aktien in kw alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongmdax gewinner und verlierer die top flop aktien in kw strongadiv classmarginverticalwelche aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titletecdax gewinner und verlierer die top flop aktien in kw alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongtecdax gewinner und verlierer die top flop aktien in kw strongadiv classmarginverticalwelche aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titledax gewinner und verlierer die top flop aktien in kw alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdax gewinner und verlierer die top flop aktien in kw strongadiv classmarginverticalwelche aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtbodytable\n\nmehr mehr\n\ndie beliebtesten toprankings\n\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titlerohstoffpreise entwicklung gewinner und verlierer in q alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongrohstoffpreise entwicklung gewinner und verlierer in q strongadiv classmarginverticalwelcher rohstoff macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titledax gewinner und verlierer die top flop aktien im juni alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdax gewinner und verlierer die top flop aktien im juni strongadiv classmarginverticalwelche aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titlediese aktien hat warren buffett in den vergangenen monaten gekauft alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdiese aktien hat warren buffett in den vergangenen monaten gekauftstrongadiv classmarginverticalwo hat der starinvestor zugeschlagendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titledax gewinner und verlierer die top flop aktien im mai alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdax gewinner und verlierer die top flop aktien im mai strongadiv classmarginverticalwelche aktie macht das rennendivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtr classtabletrtd classtabletd paddinghorizontala hreftoprankingtoprankingdetailaspinrankingimg src width height titlediese aktien befanden sich im ersten quartal im depot von bridgewater associates alt loadinglazyatdtd classtabletda hreftoprankingtoprankingdetailaspinrankingstrongdiese aktien befanden sich im ersten quartal im depot von bridgewater associatesstrongadiv classmarginverticalportfolioüberblickdivdiva classdisplaynonemd fontwhitespacenowrapmd hreftoprankingtoprankingdetailaspinrankingjetzt durchklicken span classicon iconarrowdoubleright iconscalespanaa classbutton buttonstretchmd displaynone displayinlineflexmd rolebutton hreftoprankingtoprankingdetailaspinrankingjetzt durchklickenadivtdtrtbodytable\n\nmehr top rankings mehr top rankings\n\numfrage\n\n\nsorgen sie sich um folgen der künstlichen intelligenz\n\nja\n\nnein\n\nabstimmen\n\ndirekt zu den ergebnissen direkt zu den ergebnissen\n\nquicklinks\n\n\ntable classtabletbody classtabletbodytr classtabletrtd classtabletda hrefaktienkurseaktienkurseatdtd classtabletda hrefboersenkursebeliebteste aktienatdtrtr classtabletrtd classtabletda hrefaktiendaxrealtimekurserealtimekurseatdtd classtabletda hrefindizesalle indizesatdtrtr classtabletrtd classtabletda hreftoptop atdtd classtabletda hrefindexdaxtopfloptopsflopsatdtrtr classtabletrtd classtabletda hrefinsiderdateninsiderdatenatdtd classtabletda hrefaktiendividendendividendenatdtrtr classtabletrtd classtabletda hrefprofiluebersichtportfolioatdtd classtabletdtdtrtbodytable\n\n \n\n finanzennet zero badge\n\naktien kaufen zu topkonditionen\n\naktien etfs derivate kryptos und mehr jetzt für \_euro pro trade handeln zzgl marktüblicher spreads\n\njetzt informieren\n\n finanzennet zero\n\njetzt informieren\n\n oskar app\n\nder einfache und intelligente etfsparplan\n\noskar ist der einfache und intelligente etfsparplan er übernimmt die etfauswahl ist steuersmart transparent und kostengünstig\n\njetzt mehr erfahren\n\n oskar\n\njetzt mehr erfahren\n\naktien news quick links\n\nbörsennews börsennewsaktien news aktien newsfinanznachrichten finanznachrichtendax news dax newsmdax news mdax newstecdax news tecdax newsdow jones news dow jones newsnasdaq news nasdaq newsdevisen news devisen newsdollar news dollar newseuro news euro newskryptowährungen news kryptowährungen newsbitcoin news bitcoin newsnvidia aktie news nvidia aktie newsrheinmetall aktie news rheinmetall aktie newstesla aktie news tesla aktie newsbasf aktie news basf aktie newsbayer aktie news bayer aktie newsamazon aktie news amazon aktie newssiemens energy aktie news siemens energy aktie newstui aktie news tui aktie newsallianz aktie news allianz aktie newsmicrosoft aktie news microsoft aktie newssap aktie news sap aktie newsdeutsche bank aktie news deutsche bank aktie newsapple aktie news apple aktie newscommerzbank aktie news commerzbank aktie newsplug power aktie news plug power aktie newshensoldt aktie news hensoldt aktie newsinfineon aktie news infineon aktie newspaypal aktie news paypal aktie newsrwe aktie news rwe aktie newsrenk aktie news renk aktie newslufthansa aktie news lufthansa aktie newsairbus aktie news airbus aktie newsbyd aktie news byd aktie newsbiontech aktie news biontech aktie newsthyssenkrupp aktie news thyssenkrupp aktie newsmercedes aktie news mercedes aktie newsnordex aktie news nordex aktie newsvonovia aktie news vonovia aktie newsamd aktie news amd aktie newsuniper aktie news uniper aktie newsevotec aktie news evotec aktie newsmorphosys aktie news morphosys aktie newsnovo nordisk aktie news novo nordisk aktie newspfizer aktie news pfizer aktie newsintel aktie news intel aktie newspalantir aktie news palantir aktie newscovestro aktie news covestro aktie newssiemens aktie news siemens aktie newscurevac aktie news curevac aktie newspuma aktie news puma aktie newsadidas aktie news adidas aktie newsnel aktie news nel aktie newsdaimler truck aktie news daimler truck aktie newssma solar aktie news sma solar aktie newsdelivery hero aktie news delivery hero aktie newsalibaba aktie news alibaba aktie newstelekom aktie news telekom aktie newsbat aktie news bat aktie newsbmw aktie news bmw aktie newszalando aktie news zalando aktie newssuper micro computer aktie news super micro computer aktie newspbb aktie news pbb aktie newsverbio aktie news verbio aktie newsm aktie news m aktie newsvw aktie news vw aktie news\n\nunternehmen\n\nkontakt\n\nservice\n\nhilfe\n\ninformationen\n\nimpressum tracking\n\nfolgen sie uns auf\n\n finanzennet bei instagram finanzennet bei facebook finanzennet bei youtube finanzennet bei twitter finanzennet bei linkedin finanzennet bei xing finanzennet rss feed\n\napps\n\nfinanzennet app app\n\nios android\n\n finanzennet ios app finanzennet android app\n\nwerbung\n\nfür die aufgeführten inhalte kann keine gewährleistung für die vollständigkeit richtigkeit und genauigkeit übernommen werden kursinformationen von six financial information verzögerung deutsche börse min nasdaq nyse min © finanzennet gmbh"
- text: "johnson johnson shares positive results for tar in highrisk bladder cancer pmlive\n\n \n\n \n\n \n\n \n\n \n\n advertise\n subscribe\n contact\n publications\n pme\n pme supplements\n communique\n t\n\n advertise\n subscribe\n contact\n publications\n pme\n pme supplements\n communique\n t\n\n follow follow on facebook\n follow follow on x\n follow follow on linkedin\n follow follow on rss\n\n pharmafile logo\n\n t cover\n\n diversity equity and inclusion\n\n communiqué cover \n\n pmlive\n\n t cover\n\n diversity equity and inclusion\n\n communiqué cover \n\n pmlive\n\n t cover\n\n diversity equity and inclusion\n\n communiqué cover \n\n pmlive\n\n \n news\n research\n sales\n regulatory\n healthcare\n marketing\n intelligence\n intelligence\n webinars\n podcasts\n digital handbook\n orphan drugs rare diseases\n glossary\n healthcare advertising gallery\n thought leadership\n appointments\n awards\n blogs\n digital intelligence\n smart thinking\n darwin’s medicine\n webinars\n t\n top overall\n smaller agencies\n independent agencies\n young agencies\n uk focused agencies\n about t\n pmhub\n company profiles\n press releases\n white papers and resources\n videos and podcasts\n pmhub login\n add your company\n jobs\n pme\n \n search\n \n more results\n \n advanced search\n \n\njohnson johnson shares positive results for tar in highrisk bladder cancer\n\n\nmore than cases of bladder cancer are diagnosed in the us every year\n\n pmlive\n\njohnson johnson jj has shared promising results for its investigational bladder cancer treatment approach tar at this year’s american urological association annual meeting\n\nmore than people are diagnosed with bladder cancer in the us every year with nonmuscleinvasive bladder cancer nmibc accounting for up to of all newly diagnosed cases\n\nradical cystectomy the removal of the bladder and nearby structures and organs is currently recommended for nmibc patients who fail standardofcare bacillus calmetteguérin bcg immunotherapy however as nmibc usually affects older patients many may be unwilling or unfit to undergo this procedure\n\ntar is an investigational targeted releasing system which enables the controlled release of the chemotherapy drug gemcitabine into the bladder this increases the amount of time the drug delivery system spends in the bladder and sustains local drug exposure according to jj\n\ncohort two of the phase b sunrise trial has been evaluating tar as a monotherapy in patients with bcgunresponsive highrisk nmibc with carcinoma in situ who are ineligible for or decline radical cystectomy\n\nresults demonstrated a centrally confirmed complete response cr rate of with of crs achieved at the first disease assessment at week and four of five patients who have completed two years of treatment remaining in cr\n\nthe estimated oneyear duration of response rate is with median followup in responders of weeks additionally remained in cr at the data cutoff in january and none of the responders progressed to muscleinvasive bladder cancer or metastasis\n\n“the high cr rate and durability of these responses observed in patients treated with tar underscores the potential of this treatment approach for patients with bcgunresponsive highrisk nmibc” said presenting author joseph jacob department of urology at upstate medical university\n\nsunrise is also evaluating tar which has already been granted breakthrough therapy designation by the us food and drug administration in combination with the investigational antipd monoclonal antibody cetrelimab or cetrelimab alone in the same patient population\n\nchristopher cutie vice president disease area leader bladder cancer jj innovative medicine said “these results reinforce the potential of tar to transform the treatment landscape and our ongoing dedication to address unmet needs for patients facing this challenging disease”\n\narticle by emily kimber\n\nth may \n\nfrom research\n\njohnson johnson nonmuscleinvasive bladder cancer oncology sunrise tar\n\n \n\n \n\nsubscribe to our email news alerts\n\n latest jobs from\_pharmarole\n\naccount specialist respiratory kent medway account specialist respiratory kent medway\n\nterritory sales manager ostomy care wales south mids territory sales manager ostomy care wales south mids\n\nkey account manager urology east anglia beds bucks key account manager urology east anglia beds bucks\n\nterritory sales manager north london east anglia territory sales manager north london east anglia\n\nintegrated care specialist north west yorkshire integrated care specialist north west yorkshire\n\nterritory sales manager ostomy care wales south mids territory sales manager ostomy care wales south mids\n\n \n\n \n\n \n\n latest content\n\n novo nordisk’s semaglutide approved by mhra to prevent cardiovascular event risk\n nhs figures reveal record number of people in england being diagnosed with dementia\n merck’s investigational rsv monoclonal antibody clesrovimab shown to protect infants\n gsk’s viiv shares positive headtohead results for twodrug hiv regimen dovato\n researchers develop ai model to identify breast cancer stages and progression\n\n latest intelligence\n\n the omnichannel wonderland of opportunities\n women in pharma\n dementia – risk factors research and treatment\n collaborating for change in rheumatology\n pharma’s content conundrum\n\n quick links\n\n digital handbook\n the gallery\n healthcare glossary\n how to advertise\n\n orphan drugs and rare dis\n pme supplements\n social media hub\n webinars\n\n \n\n \n\n about us\n privacy\n terms and conditions\n sitemap\n pmgroup worldwide ltd\n subscribeunsubscribe\n\n about us\n privacy\n terms and conditions\n sitemap\n pmgroup worldwide ltd\n subscribeunsubscribe\n\n \n\n blob\n\nto provide the best experiences we use technologies like cookies to store andor access device information consenting to these technologies will allow us to process data such as browsing behaviour or unique ids on this site not consenting or withdrawing consent may adversely affect certain features and functions privacy policy website terms and conditions\n\nessentialessentialstatisticsstatisticsmarketingmarketing\n\naccept cookiessave settings\n\nx\n\ncookie settings"
pipeline_tag: text-classification
inference: true
base_model: sentence-transformers/paraphrase-mpnet-base-v2
model-index:
- name: SetFit with sentence-transformers/paraphrase-mpnet-base-v2
results:
- task:
type: text-classification
name: Text Classification
dataset:
name: Unknown
type: unknown
split: test
metrics:
- type: accuracy
value: 0.43103448275862066
name: Accuracy
SetFit with sentence-transformers/paraphrase-mpnet-base-v2
This is a SetFit model that can be used for Text Classification. This SetFit model uses sentence-transformers/paraphrase-mpnet-base-v2 as the Sentence Transformer embedding model. A LogisticRegression instance is used for classification.
The model has been trained using an efficient few-shot learning technique that involves:
- Fine-tuning a Sentence Transformer with contrastive learning.
- Training a classification head with features from the fine-tuned Sentence Transformer.
Model Details
Model Description
- Model Type: SetFit
- Sentence Transformer body: sentence-transformers/paraphrase-mpnet-base-v2
- Classification head: a LogisticRegression instance
- Maximum Sequence Length: 512 tokens
- Number of Classes: 2 classes
Model Sources
- Repository: SetFit on GitHub
- Paper: Efficient Few-Shot Learning Without Prompts
- Blogpost: SetFit: Efficient Few-Shot Learning Without Prompts
Model Labels
| Label | Examples |
|---|---|
| 1 |
|
| 0 |
|
Evaluation
Metrics
| Label | Accuracy |
|---|---|
| all | 0.4310 |
Uses
Direct Use for Inference
First install the SetFit library:
pip install setfit
Then you can load this model and run inference.
from setfit import SetFitModel
# Download from the 🤗 Hub
model = SetFitModel.from_pretrained("csong97/setfit-jnj-relevancy")
# Run inference
preds = model("johnson johnson shares positive results for tar in highrisk bladder cancer pmlive
advertise
subscribe
contact
publications
pme
pme supplements
communique
t
advertise
subscribe
contact
publications
pme
pme supplements
communique
t
follow follow on facebook
follow follow on x
follow follow on linkedin
follow follow on rss
pharmafile logo
t cover
diversity equity and inclusion
communiqué cover
pmlive
t cover
diversity equity and inclusion
communiqué cover
pmlive
t cover
diversity equity and inclusion
communiqué cover
pmlive
news
research
sales
regulatory
healthcare
marketing
intelligence
intelligence
webinars
podcasts
digital handbook
orphan drugs rare diseases
glossary
healthcare advertising gallery
thought leadership
appointments
awards
blogs
digital intelligence
smart thinking
darwin’s medicine
webinars
t
top overall
smaller agencies
independent agencies
young agencies
uk focused agencies
about t
pmhub
company profiles
press releases
white papers and resources
videos and podcasts
pmhub login
add your company
jobs
pme
search
more results
advanced search
johnson johnson shares positive results for tar in highrisk bladder cancer
more than cases of bladder cancer are diagnosed in the us every year
pmlive
johnson johnson jj has shared promising results for its investigational bladder cancer treatment approach tar at this year’s american urological association annual meeting
more than people are diagnosed with bladder cancer in the us every year with nonmuscleinvasive bladder cancer nmibc accounting for up to of all newly diagnosed cases
radical cystectomy the removal of the bladder and nearby structures and organs is currently recommended for nmibc patients who fail standardofcare bacillus calmetteguérin bcg immunotherapy however as nmibc usually affects older patients many may be unwilling or unfit to undergo this procedure
tar is an investigational targeted releasing system which enables the controlled release of the chemotherapy drug gemcitabine into the bladder this increases the amount of time the drug delivery system spends in the bladder and sustains local drug exposure according to jj
cohort two of the phase b sunrise trial has been evaluating tar as a monotherapy in patients with bcgunresponsive highrisk nmibc with carcinoma in situ who are ineligible for or decline radical cystectomy
results demonstrated a centrally confirmed complete response cr rate of with of crs achieved at the first disease assessment at week and four of five patients who have completed two years of treatment remaining in cr
the estimated oneyear duration of response rate is with median followup in responders of weeks additionally remained in cr at the data cutoff in january and none of the responders progressed to muscleinvasive bladder cancer or metastasis
“the high cr rate and durability of these responses observed in patients treated with tar underscores the potential of this treatment approach for patients with bcgunresponsive highrisk nmibc” said presenting author joseph jacob department of urology at upstate medical university
sunrise is also evaluating tar which has already been granted breakthrough therapy designation by the us food and drug administration in combination with the investigational antipd monoclonal antibody cetrelimab or cetrelimab alone in the same patient population
christopher cutie vice president disease area leader bladder cancer jj innovative medicine said “these results reinforce the potential of tar to transform the treatment landscape and our ongoing dedication to address unmet needs for patients facing this challenging disease”
article by emily kimber
th may
from research
johnson johnson nonmuscleinvasive bladder cancer oncology sunrise tar
subscribe to our email news alerts
latest jobs from pharmarole
account specialist respiratory kent medway account specialist respiratory kent medway
territory sales manager ostomy care wales south mids territory sales manager ostomy care wales south mids
key account manager urology east anglia beds bucks key account manager urology east anglia beds bucks
territory sales manager north london east anglia territory sales manager north london east anglia
integrated care specialist north west yorkshire integrated care specialist north west yorkshire
territory sales manager ostomy care wales south mids territory sales manager ostomy care wales south mids
latest content
novo nordisk’s semaglutide approved by mhra to prevent cardiovascular event risk
nhs figures reveal record number of people in england being diagnosed with dementia
merck’s investigational rsv monoclonal antibody clesrovimab shown to protect infants
gsk’s viiv shares positive headtohead results for twodrug hiv regimen dovato
researchers develop ai model to identify breast cancer stages and progression
latest intelligence
the omnichannel wonderland of opportunities
women in pharma
dementia – risk factors research and treatment
collaborating for change in rheumatology
pharma’s content conundrum
quick links
digital handbook
the gallery
healthcare glossary
how to advertise
orphan drugs and rare dis
pme supplements
social media hub
webinars
about us
privacy
terms and conditions
sitemap
pmgroup worldwide ltd
subscribeunsubscribe
about us
privacy
terms and conditions
sitemap
pmgroup worldwide ltd
subscribeunsubscribe
blob
to provide the best experiences we use technologies like cookies to store andor access device information consenting to these technologies will allow us to process data such as browsing behaviour or unique ids on this site not consenting or withdrawing consent may adversely affect certain features and functions privacy policy website terms and conditions
essentialessentialstatisticsstatisticsmarketingmarketing
accept cookiessave settings
x
cookie settings")
Training Details
Training Set Metrics
| Training set | Min | Median | Max |
|---|---|---|---|
| Word count | 275 | 1267.35 | 4278 |
| Label | Training Sample Count |
|---|---|
| 0 | 10 |
| 1 | 10 |
Training Hyperparameters
- batch_size: (16, 16)
- num_epochs: (2, 2)
- max_steps: -1
- sampling_strategy: oversampling
- num_iterations: 20
- body_learning_rate: (2e-05, 2e-05)
- head_learning_rate: 2e-05
- loss: CosineSimilarityLoss
- distance_metric: cosine_distance
- margin: 0.25
- end_to_end: False
- use_amp: False
- warmup_proportion: 0.1
- seed: 42
- eval_max_steps: -1
- load_best_model_at_end: False
Training Results
| Epoch | Step | Training Loss | Validation Loss |
|---|---|---|---|
| 0.02 | 1 | 0.2562 | - |
| 1.0 | 50 | 0.0028 | - |
| 2.0 | 100 | 0.0008 | - |
Framework Versions
- Python: 3.11.0rc1
- SetFit: 1.0.3
- Sentence Transformers: 2.6.1
- Transformers: 4.39.2
- PyTorch: 2.2.2+cpu
- Datasets: 2.18.0
- Tokenizers: 0.15.0
Citation
BibTeX
@article{https://doi.org/10.48550/arxiv.2209.11055,
doi = {10.48550/ARXIV.2209.11055},
url = {https://arxiv.org/abs/2209.11055},
author = {Tunstall, Lewis and Reimers, Nils and Jo, Unso Eun Seo and Bates, Luke and Korat, Daniel and Wasserblat, Moshe and Pereg, Oren},
keywords = {Computation and Language (cs.CL), FOS: Computer and information sciences, FOS: Computer and information sciences},
title = {Efficient Few-Shot Learning Without Prompts},
publisher = {arXiv},
year = {2022},
copyright = {Creative Commons Attribution 4.0 International}
}